NEW YORK – A case study using Natera's personalized circulating tumor DNA monitoring assays has provided insights into the ways that such technology could help oncologists monitor and more precisely treat patients with esophageal cancers.
Although esophageal cancer is not a tumor type with an established use-case for liquid biopsy surveillance right now, there is a growing wave of interest in extending these technologies to the gastrointestinal cancer space, and potentially across other cancer types as well.